Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Operating Expenses (2019 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Other Operating Expenses for 13 consecutive years, with $35.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses rose 14.69% year-over-year to $35.5 million, compared with a TTM value of $124.8 million through Dec 2025, up 17.44%, and an annual FY2025 reading of $124.8 million, up 17.44% over the prior year.
  • Other Operating Expenses was $35.5 million for Q4 2025 at Catalyst Pharmaceuticals, up from $32.0 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $35.5 million in Q4 2025 and bottomed at $4.5 million in Q2 2021.
  • Average Other Operating Expenses over 5 years is $18.6 million, with a median of $21.2 million recorded in 2023.
  • The sharpest move saw Other Operating Expenses grew 9.79% in 2021, then skyrocketed 179.75% in 2023.
  • Year by year, Other Operating Expenses stood at $7.3 million in 2021, then skyrocketed by 60.25% to $11.8 million in 2022, then skyrocketed by 111.19% to $24.9 million in 2023, then grew by 24.61% to $31.0 million in 2024, then grew by 14.69% to $35.5 million in 2025.
  • Business Quant data shows Other Operating Expenses for CPRX at $35.5 million in Q4 2025, $32.0 million in Q3 2025, and $30.0 million in Q2 2025.